Literature DB >> 33909542

Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses.

Amandine Bovay1, Silvia A Fuertes Marraco2, Daniel E Speiser2.   

Abstract

By preventing infectious diseases, vaccines contribute substantially to public health. Besides, they offer great opportunities to investigate human immune responses. This is particularly true for live-attenuated virus vaccines which cause resolving acute infections and induce robust immunity. The fact that one can precisely schedule the time-point of vaccination enables complete characterization of the immune response over time, short-term and over many years. The live-attenuated Yellow Fever virus vaccine strain YF-17D was developed in the 1930's and gave rise to the 17D-204 and 17DD vaccine sub-strains, administered to over 600 million individuals worldwide. YF vaccination causes a systemic viral infection, which induces neutralizing antibodies that last for a lifetime. It also induces a strong T cell response resembling the ones of acute infections, in contrast to most other vaccines. In spite of its use since 1937, learning how YF vaccination stimulates such strong and persistent immune responses has gained substantial knowledge only in the last decades. Here we summarize the current state of knowledge on the immune response to YF vaccination, and discuss its contribution as a human model to address complex questions on optimal immune responses.

Entities:  

Keywords:  B cells; Immune response; T cells; Yellow Fever vaccination

Year:  2021        PMID: 33909542     DOI: 10.1080/21645515.2021.1891752

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  3 in total

Review 1.  Role of Lectin in the Response of Aedes aegypti Against Bt Toxin.

Authors:  Intikhab Alam; Khadija Batool; Aisha Lawan Idris; Weilong Tan; Xiong Guan; Lingling Zhang
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

2.  The efficacy of a 2,4-diaminoquinazoline compound as an intranasal vaccine adjuvant to protect against influenza A virus infection in vivo.

Authors:  Kyungseob Noh; Eun Ju Jeong; Timothy An; Jin Soo Shin; Hyejin Kim; Soo Bong Han; Meehyein Kim
Journal:  J Microbiol       Date:  2022-04-18       Impact factor: 2.902

Review 3.  What Constitutes Protective Immunity Following Yellow Fever Vaccination?

Authors:  Jolynne Mokaya; Derick Kimathi; Teresa Lambe; George M Warimwe
Journal:  Vaccines (Basel)       Date:  2021-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.